Skip to main content
S&P 5007,551.81-0.45%DOW51,461.90-1.21%NASDAQ25,978.42-0.01%BTC$76,346.00+0.85%ETH$2,420.07+0.87%GOLD$4,327.00-1.38%OIL$101.32-1.08%
Smart Investors Daily
AN

NASDAQ · ANL

Adlai Nortye Ltd.

Healthcare · Biotechnology

$15.52

Up+$0.52 (+3.47%)

Updated Sep 17, 2026, 7:43 AM

SID Score

5.5/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
245.52M
P/E ratio
-1.61
Dividend yield
0.00%
52-week range
$0.88 – $17.25
Volume
220.83K
Avg. volume
920.81K

Price performance

ANL price history

1M range · 20 trading sessions · Daily adjusted prices

ANL closed at $15.52 after 20 trading sessions, up 8.30% for the selected period.

Last close
$15.52
Period change
+8.30%
Period low
$13.63
Period high
$15.93
Daily close
View OHLC price history
ANL OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 16, 2026$15.16$15.75$14.925$15.52220.83K
Sep 15, 2026$15.92$16.19$14.87$15.00171.3K
Sep 14, 2026$15.18$16.10$15.13$15.93175.55K
Sep 11, 2026$15.32$16.00$15.20$15.21228.74K
Sep 10, 2026$14.97$15.78$14.70$15.09318.22K
Sep 9, 2026$15.44$15.94$14.42$14.695161.83K
Sep 8, 2026$15.12$16.12$14.82$15.51404.96K
Sep 4, 2026$14.69$16.02$14.5529$15.01308.57K
Sep 3, 2026$13.95$14.79$13.779$14.7577.06K
Sep 2, 2026$13.76$14.20$13.48$13.85577.71K
Sep 1, 2026$14.02$14.41$13.32$13.63104.47K
Aug 31, 2026$13.84$14.44$13.26$14.19139.19K
Aug 28, 2026$14.41$14.46$13.53$13.82165.03K
Aug 27, 2026$14.88$15.20$14.05$14.32137.01K
Aug 26, 2026$13.70$15.105$13.50$15.06149.69K
Aug 25, 2026$14.09$14.29$13.55$13.74100.2K
Aug 24, 2026$13.66$14.40$13.14$14.16185.76K
Aug 21, 2026$13.97$14.275$13.52$13.70103.05K
Aug 20, 2026$14.30$14.30$13.56$13.72117.2K
Aug 19, 2026$14.25$14.77$14.035$14.33150.54K

Latest ANL news

The latest Smart Investors Daily articles mentioning ANL.

Stock researchCompany · Overview

ANL research

Overview

Company profile and research snapshot.

Company profile

Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$9.00
Implied upside
—
Analysts
—
ANL recent ratings
DateFirmRatingTarget
Sep 10, 2026JefferiesBuy—
Sep 8, 2026HC Wainwright & Co.Buy—
Jun 22, 2026Cantor FitzgeraldOverweight—
May 28, 2026OppenheimerOutperform—
May 14, 2026Jones TradingBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 15, 2026

4.8x P B? Adlai Nortye Group (ANL) On Its AN4035 Trial Progress

Why the AN4035 trial move matters for Adlai Nortye Group stock Adlai Nortye Group (NasdaqGM:ANL) has just dosed the first patient in its global Phase I trial for AN4035 and secured a Study May Proceed letter from the FDA, clearing expansion into the United States. The fresh AN4035 milestone comes after a strong run in Adlai Nortye Group’s stock, with a very large year-to-date share price return and a 1-year total shareholder return of about 8x. Recent 30-day and 90-day share price returns of...

Yahoo · Sep 8, 2026

Adlai Nortye Announces First Patient Dosed in Australia and U.S. FDA IND Clearance for AN4035, a First-in-Class Pan-RAS(ON) Inhibitor-Based ADC

First-in-class CEACAM5-targeting ADC armed with a pan-RAS(ON) inhibitor – designed for tumor-selective RAS pathway inhibition First patient dosed in Australia; global Phase I initiated U.S. FDA cleared IND with "Study-May-Proceed" letter SINGAPORE and NORTH BRUNSWICK, N.J., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Adlai Nortye Group Ltd. (NASDAQ: ANL) (“Adlai Nortye” or the “Company”), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced tha

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By